BridgeBio Oncology Unveils Preclinical BBO-10203 and Phase 1 BBO-11818 at AACR
BridgeBio Oncology will present two RAS-pathway therapeutics at the AACR Annual Meeting April 17-22, featuring BBO-10203’s oral data on PI3Kα/AKT inhibition in HER2+ models. The company will also showcase BBO-11818’s preclinical anti-tumor activity as it advances in the Phase 1 KONQUER-101 trial for KRAS-mutant tumors.
1. AACR Annual Meeting Participation
BridgeBio Oncology will present two abstracts at the AACR Annual Meeting April 17-22, 2026 in San Diego. The company plans an oral presentation on April 21 and a poster on April 22 covering its pipeline of RAS-pathway therapeutics.
2. BBO-10203 Oral Presentation Details
The oral session on April 21 (2:30-4:30 p.m. PT) will feature BBO-10203, a first-in-class small molecule that disrupts RAS-PI3Kα interaction to inhibit PI3Kα/AKT signaling in HER2+ models (Abstract 6780, Upper Level Ballroom 6DE). BBO-10203 is currently in the Phase 1 BREAKER-101 trial for HER2-positive and KRAS-mutant cancers.
3. BBO-11818 Poster Presentation Overview
The poster session on April 22 (9:00 a.m.-12:00 p.m. PT) will present BBO-11818, an orally bioavailable non-covalent pan-KRAS inhibitor with potent anti-tumor activity in KRASG12D/V models (Poster 7104, Section 13). BBO-11818 is under evaluation in the Phase 1 KONQUER-101 trial for locally advanced or metastatic KRAS-mutant solid tumors.